Should You Buy Procept Biorobotics Corp (PRCT) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Hold
Latest Price
29.120
1 Day change
-3.00%
52 Week Range
75.290
Analysis Updated At
2026/01/26
Procept BioRobotics Corp (PRCT) is not a strong buy at this moment for a beginner investor with a long-term strategy. Despite some positive financial growth trends and analyst optimism for the long term, the current technical indicators and hedge fund selling suggest caution. The stock's pre-market performance is modest, and there are no strong proprietary trading signals to act on today. For a long-term investor, it may be worth monitoring for a better entry point.
Technical Analysis
The technical indicators for PRCT are bearish. The MACD is negative and expanding downward, the RSI is neutral at 27.072, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 29.392, with resistance levels at 31.682 and 33.972.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
The open interest put-call ratio of 0.66 and option volume put-call ratio of 0.45 suggest a slightly bullish sentiment in the options market. However, the implied volatility is high, indicating significant uncertainty in the stock's future price movements.
Technical Summary
Sell
9
Buy
3
Positive Catalysts
Revenue growth of 42.76% YoY in Q3
Gross margin improvement to 64.81%, up 2.48% YoY.
Analyst optimism for long-term utilization growth and market opportunity in 2026 and beyond.
Recent analyst ratings from UBS and Truist maintain a Buy rating with price targets of $62 and $47, respectively.
Neutral/Negative Catalysts
Hedge funds are selling heavily, with a 465.92% increase in selling activity last quarter.
Insider trading trends are neutral, providing no positive reinforcement.
Downgrades from BofA and reduced price targets from multiple analysts.
Slowing utilization growth and potential near-term disruption due to organizational changes.
Bearish technical indicators and pre-market price performance.
Financial Performance
In Q3 2025, Procept BioRobotics demonstrated strong revenue growth of 42.76% YoY, reaching $83.33 million. However, net income remains negative at -$21.41 million, with a slight improvement of 2.08% YoY. EPS dropped by 5.00% YoY to -0.38. Gross margin increased to 64.81%, reflecting operational efficiency improvements.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Analysts are mixed but lean towards a positive long-term outlook. UBS initiated coverage with a Buy rating and a $62 price target, citing underappreciated utilization growth and market opportunity. Truist also maintains a Buy rating with a $47 price target. However, BofA downgraded the stock to Neutral with a $38 price target, citing slowing utilization growth and near-term disruptions.
Wall Street analysts forecast PRCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRCT is 51.75 USD with a low forecast of 38 USD and a high forecast of 65 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast PRCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRCT is 51.75 USD with a low forecast of 38 USD and a high forecast of 65 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 30.020
Low
38
Averages
51.75
High
65
Current: 30.020
Low
38
Averages
51.75
High
65
Truist
Richard Newitter
Buy
downgrade
$50 -> $47
AI Analysis
2025-12-18
Reason
Truist
Richard Newitter
Price Target
$50 -> $47
AI Analysis
2025-12-18
downgrade
Buy
Reason
Truist analyst Richard Newitter lowered the firm's price target on Procept BioRobotics to $47 from $50 and keeps a Buy rating on the shares as part of a broader research note previewing 2026 for MedTech. The firm is more positive on the industry heading into next year given a more attractive relative sector valuation, though it also sees the possibility of it being a "source" vs. a destination of new healthcare investment flows, the analyst tells investors in a research note. Truist adds it prefers names with 2026 catalysts fueling durable revenue acceleration or out-of-favor near-term narratives.
UBS
Danielle Antalffy
Buy
initiated
$62
2025-12-12
Reason
UBS
Danielle Antalffy
Price Target
$62
2025-12-12
initiated
Buy
Reason
UBS analyst Danielle Antalffy initiated coverage of Procept BioRobotics with a Buy rating and $62 price target. The firm's key onion leader checks provide conviction in the company's utilization growth in 2026 and 2027. It views the recent selloff in the shares as a buying opportunity. Procept's focus on driving utilization on its existing installed base, underpenetrated system placement market, and mix-driven margin expansion are underappreciated by the market, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PRCT
